All In Biotech

Drug Trial Radar · NCT02148796

Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness

Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of ORal Bacterial EXtract for the Prevention of Wheezing Lower Respiratory Tract Illness (ORBEX)

Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 822 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

822

Actual

Start

Jan 1, 2017

Primary completion

Jan 30, 2026

Study completion Jan 30, 2026

Sponsor

Lead sponsor
University of ArizonaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 28, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 18 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate if Broncho-Vaxom® given to high risk infants for 10 days, monthly, for two consecutive years can increase time to occurrence of the first episode of wheezing lower respiratory tract illness (WLRI) during a three year observation period off therapy.

Conditions

  • Asthma
  • Wheezing

Interventions

  • Broncho-Vaxom (BV)Drug

    Active Ingredient: Lyophilised bacterial extract; Chemical Name: OM-85 BV; Strength: 3.5 mg; Excipients: bacterial extract, propyl gallate, sodium glutamate, mannitol, pregelatinised starch, magnesium stearate; Appearance: Blue and white capsule; Dosage Form: 3.5 mg capsule; Manufacturer: OM Pharma, Switzerland (OM stands for Omnia Medicamenta) Storage: Store in the original package

  • PlaceboOther

    A placebo capsule will be used that will be indistinguishable from the active study drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The time to the occurrence of the first WLRI episode in the observation period while not receiving study drugTime frame: ages 30 to 42 months at the end of treatment; ages 66 to 78 months at completion

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • University of Arizona

    Tucson, Arizona

  • University of California San Francisco, Benioff Children's Hospital

    Oakland, California

  • Children's National Health System

    Washington D.C., District of Columbia

  • Emory University

    Atlanta, Georgia

  • Boston Children's Hospital, Harvard University

    Boston, Massachusetts

  • Washington University

    St Louis, Missouri

  • Columbia University

    New York, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • Cincinnati Children's Hospital & Medical Center

    Cincinnati, Ohio

  • University of Wisconsin

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.